International Agency for Dr Maimuna Mendy (MM) Cancer, virology, biomarkers, Research on Cancer (IARC), proteomics France Institute National de la Sante et Prof Fabien Zoulim Infectious diseases, HBV de la Recherché Medicale Dr Isabelle Chemin (IC) virology (INSERM), France Xeptagen Inc. Italy Dr Giorgio Fassina Diagnostic development, biomarkers MRC Gambia, Gambia Prof. Clinical studies Umberto D’Alesssandro (UDA) Le Dantec Hospital, Senegal Prof Soulemayne Mboup Clinical studies (SMB) Royal Victoria Teaching Hospital Dr Ignatius Baldeh (IB) Clinical studies Jos University Teaching Hospital Prof Edith Okeke (EO) Clinical studies (JUTH), Jos, Nigeria The project has been conducted within 7 workpackages (WP) summarized in Table 2: Table : PROLIFICA Workpackages Workpackage Lead unit/person Description WP1 Imperial College (MT) Coordination & management WP2 Imperial College (MM) HCC control study dataset HCC case study WP3 Imperial College (MT), Treatment study Anti- viral treatment cohort MRC (UDA) and Senegal (WATCH) study (SMB) WP4 Imperial College (STR) Novel markers for liver Biomarker discovery and IARC (MM) cancer validation mechanistic investigations through proteomics WP5 Imperial College (STR) Confirmed list of Development of IARC (MM) biomarkers metabonomic markers for the diagnosis of HCC WP6 INSERM, Lyon, France HBV molecular and (IC) serodiagnostics WP7 All partners Capacity building As lead Partner, the main role of Imperial College has been to act as the overall administrative co-ordinator of the project to ensure efficient collaboration, exchange of information and knowledge and fulfilment of ethical, regulatory and bio-safety rules. In addition, Imperial monitors the progress of the project, anticipating possible hurdles and working with the partners to find solutions. Specifically this includes detailing the overall work programme and budget, co-ordinating and monitoring scientific and financial reports, collecting and compiling results and organising project meetings.
International Agency for Research on Cancer (IARC), France Dr Maimuna Mendy (MM) Cancer, virology, biomarkers, proteomics Institute National de la Sante et de la Recherché Medicale (INSERM), France Prof Fabien Zoulim Dr Isabelle Chemin (IC) Infectious diseases, HBV virology Xeptagen Inc. Italy Dr Giorgio Fassina Diagnostic development, biomarkers MRC Gambia, Gambia Prof. Umberto D’Alesssandro (UDA) Clinical studies Le Dantec Hospital, Senegal Prof Soulemayne Mboup (SMB) Clinical studies Royal Victoria Teaching Hospital Dr Ignatius Baldeh (IB) Clinical studies Jos University Teaching Hospital (JUTH), Jos, Nigeria Prof Edith Okeke (EO) Clinical studies The project has been conducted within 7 workpackages (WP) summarized in Table 2: Table : PROLIFICA Workpackages Workpackage Lead unit/person Description WP1 Imperial College (MT) Coordination & management WP2 HCC case study Imperial College (MM) HCC control study dataset WP3 Anti- viral treatment cohort (WATCH) study Imperial College (MT), MRC (UDA) and Senegal (SMB) Treatment study WP4 Biomarker discovery and mechanistic investigations through proteomics Imperial College (STR) IARC (MM) Novel markers for liver cancer validation WP5 Development of metabonomic markers for the diagnosis of HCC Imperial College (STR) IARC (MM) Confirmed list of biomarkers WP6 INSERM, Lyon, France (IC) HBV molecular and serodiagnostics WP7 All partners Capacity building As lead Partner, the main role of Imperial College has been to act as the overall administrative co-ordinator of the project to ensure efficient collaboration, exchange of information and knowledge and fulfilment of ethical, regulatory and bio-safety rules. In addition, Imperial monitors the progress of the project, anticipating possible hurdles and working with the partners to find solutions. Specifically this includes detailing the overall work programme and budget, co-ordinating and monitoring scientific and financial reports, collecting and compiling results and organising project meetings.
final1-final-report-prolifica-25th-april-2016.docx